Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2022 - 2025)

Corvus Pharmaceuticals has reported Accumulated Expenses over the past 4 years, most recently at $715000.0 for Q3 2025.

  • Quarterly results put Accumulated Expenses at $715000.0 for Q3 2025, down 83.04% from a year ago — trailing twelve months through Sep 2025 was $715000.0 (down 83.04% YoY), and the annual figure for FY2024 was $3.7 million, up 444.59%.
  • Accumulated Expenses for Q3 2025 was $715000.0 at Corvus Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CRVS hit a ceiling of $6.4 million in Q2 2022 and a floor of $589000.0 in Q1 2024.
  • Median Accumulated Expenses over the past 4 years was $1.1 million (2022), compared with a mean of $2.4 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 89.52% in 2024 and later surged 633.97% in 2025.
  • Corvus Pharmaceuticals' Accumulated Expenses stood at $1.1 million in 2022, then crashed by 38.54% to $684000.0 in 2023, then skyrocketed by 444.59% to $3.7 million in 2024, then plummeted by 80.81% to $715000.0 in 2025.
  • The last three reported values for Accumulated Expenses were $715000.0 (Q3 2025), $5.0 million (Q2 2025), and $3.9 million (Q1 2025) per Business Quant data.